New stable antibodies created

June 29, 2012 in Medications

(Medical Xpress) -- Australian scientists have overcome one of the most pressing problems facing the pharmaceutical industry – how to create antibodies that are stable enough to meet stringent requirements necessary for production in large quantities, injection into patients and long-term storage.

Members of the Antibody Engineering Laboratory at Sydney’s Garvan Institute of Medical Research – Dr Daniel Christ and PhD students Kip Dudgeon and Romain Rouet – have developed specific mutations that universally increase the stability of antibody molecules. The breakthrough finding is published today in the early online edition of the Proceedings of the Academy of Science (PNAS), the journal of the United States National Academy of Sciences.



“When we talk to collaborators in industry, we find that 30-50% of the antibody-based drugs they develop have to be put on hold because they don’t meet quality tests that the companies or regulatory agencies such as the US Food and Drug Administration, require before marketing or approving these molecules,” said Dr Christ.

“Until now, the issue of antibody instability has been tackled on a case-by-case basis, which is only tinkering with the problem. When you’re dealing with such a diverse population of molecules, you have to make sure that the method you develop is generally applicable – and that’s what we’ve done.”



Produced by the immune system in response to infection there can be as many as 100 million different kinds of in the circulation of a single human being.

Antibodies have ‘constant regions’ and ‘variable regions’, the latter determining the binding specificity of the molecule. The shape of the variable region will exactly match the ‘antigen’, or invader, in the same way as a lock matches a key.

With infinite variability of antibody structure comes varying levels of stability. It is fairly common, therefore, to have an antibody that is very good at binding to a specific antigen, but which is also very unstable. The mutations created by the Garvan team fix the stability problem without compromising the antigen binding properties of an antibody. 

Antibodies consist of two chains – a heavy and a light chain – and Dr Christ emphasises that mutations have to work with each chain individually and both chains in combination.

“Typically you’d have both chains present in a therapeutic molecule, as well as additional biological activity, such as the ability to bind to a cancer target,” he said.

“Our challenge was to maintain biological activity under very unnatural conditions, for which antibodies were not optimised by evolution. It is really when you take these molecules out of their natural environment, purify and concentrate them, that stresses become apparent. When used as a drug, antibodies are formulated at very high concentrations, for instance for delivery in a small syringe. You end up with an almost honey-like, highly viscous preparation. Under these conditions, antibodies can stick to surfaces like tubing and become entangled with one another. Our mutations make them much less sticky, much less entangled. They also make the antibodies more robust against common storage methods such as freeze drying.” 



The next step for the Garvan team will be to work with colleagues in the to improve the stability of antibody therapeutics for the treatment of cancer and inflammatory conditions.

Journal reference: Proceedings of the National Academy of Sciences search and more info website

Provided by Garvan Institute search and more info website

4.3 /5 (6 votes)  

Filter


Move the slider to adjust rank threshold, so that you can hide some of the comments.


Display comments: newest first

nanotech_republika_pl
Jul 01, 2012

Rank: not rated yet
This is great news! Especially for monoclonal antibodies, which are such a star for potential therapies for many diseases including all kinds of cancer, but very often outrageously expensive.
Rank 4.3 /5 (6 votes)
Relevant PhysicsForums posts

More news stories

US adviser on board of firm that sold anthrax drug

(AP)—Former Navy Secretary Richard J. Danzig, who has served as a bio-warfare adviser to the president, the Pentagon, and the Department of Homeland Security, urged the government to stockpile an anti-anthrax drug while ...

Medications created 4 hours ago | popularity 5 / 5 (1) | comments 0

Acne pill benefits outweigh blood clot risk: EU agency

Europe's medicines watchdog said Friday the benefits of acne drug Diane-35, also widely used as a contraceptive, outweigh the risk of developing blood clots in the veins—when correctly prescribed.

Medications created May 17, 2013 | popularity not rated yet | comments 0

First influenza vaccine brought to clinical testing

Singapore's Agency for Science, Technology and Research (A*STAR) and Switzerland's Cytos Biotechnology AG today announced that the first healthy volunteer has been dosed in a Phase 1 clinical trial with their ...

Medications created May 17, 2013 | popularity 5 / 5 (1) | comments 0

Aspirin not always best treatment for many individuals

(Medical Xpress)—An aspirin a day may not always keep heart disease away, say two University of Florida cardiologists. But a new algorithm they have developed outlines factors physicians should weigh as ...

Medications created May 16, 2013 | popularity 3.5 / 5 (2) | comments 0 | with audio podcast

FDA: lower ambien's dose to prevent drowsy driving

(HealthDay)—The U.S. Food and Drug Administration has approved new, lower-dose labeling for the popular sleep drug Ambien (zolpidem) in an effort to cut down on daytime drowsiness that could be a hazard ...

Medications created May 15, 2013 | popularity not rated yet | comments 0


Team finds mechanism linking key inflammatory marker to cancer

In a new study described in the journal Oncogene, researchers reveal how a key player in cell growth, immunity and the inflammatory response can be transformed into a primary contributor to tumor growth.

Rise in type 2 diabetes amongst young

The number of young people diagnosed with type 2 diabetes has seen the sharpest rise over the last twenty years compared to a background of a general increase across the board, new University research has ...

Inflammatory bowel disease raises risk of melanoma

Patients with inflammatory bowel disease (IBD) are at higher risk of melanoma, a form of skin cancer, report researchers at Mayo Clinic. Researchers found that IBD is associated with a 37 percent greater risk for the disease. ...

Source of infection affects hospital mortality in septic shock patients in the ICU

In ICU patients who have septic shock, the anatomic source of infection has a strong effect on the chances of survival, according to a new study from researchers in Canada.

Vitamin D could provide new and effective treatments for asthma

(Medical Xpress)—Scientists at King's College London have discovered that Vitamin D has the potential to significantly reduce the symptoms of asthma. The study, led by Professor Catherine Hawrylowicz from ...

Research uncovers a potential role of two proteins in diabetes

(Medical Xpress)—Flinders University researchers are breaking new ground in a decade-long journey to pinpoint the function of two closely related proteins.